Page 7 - Global External News Today

Investegate announcements from INVENTIVA, Inventiva announces the screening of the first patient in LEGEND, a Phase IIa combination trial with lanifibranor and empagliflozin in patients with NASH and T2D

The Phase IIa Proof-of-Concept study is designed to assess the safety and efficacy of lanifibranor in combination with the SGLT2 inhibitor empagliflozin for the treatment of patients with non-cirrhotic

Inventiva successfully raised approximately €14.6 million through a combination of its ATM Program for €9.3 million and new State-backed bank financing for €5.3 millionIn accordance with the terms of the

Investegate announcements from INVENTIVA, Update on Inventivas cash position and on the finance documentation with the European Investment Bank

Press release content from Business Wire. The AP news staff was not involved in its creation.

Press release content from Business Wire. The AP news staff was not involved in its creation.

Update on Inventiva's NATiV3 Phase III clinical trial evaluating lanifibranor in patients with NASH and fibrosis (stage F2/F3) non-cirrhotic by Prof. Sven FrancqueUpdate on the current NASH landscape by

Investegate announcements from INVENTIVA, Inventiva to host a webcast with Key Opinion Leaders following the EASL International Liver Congress™ 2022

Press release content from Business Wire. The AP news staff was not involved in its creation.

Investegate announcements from INVENTIVA, Inventiva announces three scientific presentations at the EASL International Liver Congress™ 2022